Then Wolchok put her in a trial testing ipilimumab with an experimental Medarex vaccine.
But then Memorial's Wolchok put her on an experimental drug called ipilimumab that aims to trigger the immune system.
Bristol-Myers Squibb got some exciting news from a study on experimental drug ipilimumab.
So, all other things being equal, the ipilimumab compound would bring an additional 5% growth if it hits the most bullish of targets.
Drugs that boost the immune system against cancer, such the melanoma drug ipilimumab from Bristol-Myers Squibb, could also get around the many-gene-defects problem.
Ipilimumab from Bristol-Myers Squibb stimulates the immune system against cancer.
Pfizer's drug tremelimumab and Bristol-Myers Squibb's ipilimumab are antibodies to a protein called CTLA-4 (cytotoxic T-lymphocyte antigen-4) that acts as an emergency brake to prevent killer T cells from attacking healthy tissue.
Most trials of ipilimumab to date have been in advanced melanoma, where a small percentage of patients have experienced spectacular long-lasting remissions, even as the drug appears to do relatively little for the majority.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has determined that additional time is required to complete the review of the biologics license application (BLA) for ipilimumab in pre-treated advanced melanoma, and has moved its decision date from December 25, 2010 to March 26, 2011.
In recent years, evidence has built that the immune system can sometimes attack and kill cancer cells--sometimes--but that cancer finds ways to fight back and evade or blunt the attack. (See "Cancer Miracles") For some people with advanced cancer, ipilimumab may be just enough to trigger a full-fledged anti-tumor attack.
应用推荐